Bristol-Myers’s Drug Combination Boosts Lung Cancer BenefitBy
Opdivo plus Yervoy shrinks tumors in 39% to 47% of patients
Twelve of 13 patients with PD-L1 biomarker responded to drugs
The combination of two Bristol-Myers Squibb Co. drugs that markedly improved the treatment of melanoma appears to have the same benefit for patients with the most common and often deadly form of lung cancer.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.